September 20th 2024
The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
PFS Three Times Longer With Ceritinib Than With Chemotherapy in ALK+ NSCLC
October 10th 2016Progression-free survival (PFS) was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced <em>ALK</em>-positive non–small cell lung cancer (NSCLC) who progressed after first-line crizotinib.
Read More
Pembrolizumab Data Will Change Management of NSCLC
October 9th 2016Single-agent pembrolizumab (Keytruda) reduced the risk of death by 40% and improved progression-free survival (PFS) by 4.3 months compared with doublet chemotherapy for untreated patients with advanced non–small cell lung cancer (NSCLC) with PD-L1 expression on ≥50% of cells, according to findings from the phase III KEYNOTE-024 trial.
Read More
Tools Available for Predicting Risk in Early Stage Lung Cancer
October 8th 2016Benjamin P. Levy, MD, medical director of thoracic medical oncology for Mount Sinai Health Systems and the associate medical director of the cancer clinical trials office for Mount Sinai Hospital, New York, discusses the tools currently available for predicting mortality risk in patients with early stage lung cancer.
Watch
Immunotherapies Combined With Lung Cancer Treatments Could Be Practice Changing
October 6th 2016Recent randomized clinical trials that have combined immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy for the treatment of patients with lung cancer have shown promising results for these combinations.
Read More
Capmatinib Demonstrates Early Signals of Efficacy in Advanced NSCLC
October 5th 2016The c-MET inhibitor capmatinib (INC280) demonstrated early signals of efficacy with an overall response rate (ORR) of 20% when administered to patients with advanced c-MET–dysregulated non–small cell lung cancer (NSCLC).
Read More
Rizvi Recaps Recent Immunotherapy Trials in NSCLC
October 4th 2016In an interview with <em>Targeted Oncology</em>, Naiyer Rizvi, MD, director of Thoracic Oncology and Immunotherapy at Columbia University Medical Center, discusses data from the phase III KEYNOTE-024 trial and expressed his optimism about immunotherapy in the NSCLC field.
Read More
Ceritinib Improves Progression-Free Survival in ALK+ NSCLC
September 26th 2016According to results from the phase III ASCEND-4 trial, ceritinib (Zykadia) improved progression-free survival (PFS) compared with standard chemotherapy as a first-line treatment for patients with <em>ALK</em>-positive non–small cell lung cancer (NSCLC)
Read More